technologynetworks10m
FDA Approves First Schizophrenia Treatment With a Novel Target in 70 Years
The US Food and Drug Administration has granted approval to Bristol-Myers Squibb’s drug Cobenfy® (xanomeline and trospium ...
Cure Today15m
Supplemental New Drug Application Submitted for Nubeqa in Prostate Cancer Subset
The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.
Severity of various FDA product recalls including Class I which can cause death, serious illness
Hundreds of foods are recalled by the FDA every year. Food recalls could fall into different categories, depending on how ...
The Financial Express35m
Bristol Myers gets USFDA nod for new type of schizophrenia drug
Schizophrenia causes persistent delusions and hallucinations and significantly impairs the way patients perceive reality.
Bristol Myers Stock Jumps. Why FDA Approval for Its Schizophrenia Drug Is Groundbreaking.
Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This ...
kffhealthnews41m
Antipsychotic Drug Cobenfy Wins FDA Approval For Schizophrenia Treatment
The Bristol Myers Squibb medicine is said relieve symptoms without causing some of the harsh side effects of drugs already in use. Meanwhile, thousands of patients allege in a lawsuit that drugs used ...
New schizophrenia drug could ‘change the lives of millions of people’
The US Food and Drug Administration has approved the new drug Cobenfy, which is owned by pharmaceutical firm Bristol Myers ...
Plastics News53m
Aptar works with FDA on chemical-absorbing film, expands in New York
The U.S. Food & Drug Administration has accepted Aptar Pharma's N-Sorb nitrosamine mitigation solution into its Emerging ...
Investor's Business Daily on MSN53m
Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout
Bristol-Myers Squibb won Food and Drug Administration approval late Thursday for its novel schizophrenia drug, Cobenfy. BMY ...
Managed Healthcare Executive56m
FDA Approves the Oral Medication KarXT for Schizophrenia
KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.